Bridge Biotherapeutics Confident In IPF Contender As It Seeks Global Partner

Big Pharma Licensing Talks Underway

 
• By Jung Won Shin

The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.

James Jungkue Lee, President and CEO of Bridge Biotherapeutics Inc.
First Korean Bioventure To Speak At The Main JPM Healthcare Conference Session (Bridge Biotherapeutics Inc.)

More from South Korea

More from Therapy Areas